RegenLife Centers · Physician-led care
Migraine and Headache Treatment Cincinnati OH
Nerve Blocks and Beyond
Published on October 17th, 2026


The patient who has lived with migraines for a decade knows exactly how it unfolds: the aura that arrives like a weather warning twenty minutes before the pain, the retreat to a darkened room, the nausea that makes medication feel like a gamble, and the next-day hangover that makes recovery nearly as disabling as the episode itself. What most of these patients have never been told is that interventional procedures targeting the specific neurological and structural sources of their migraines exist, procedures that have been proven in clinical trials to abort acute attacks, reduce chronic frequency, and restore function where a medication trial alone reliably fails.
Migraine and headache treatment in Cincinnati, OH at RegenLife Centers for Integrative Pain & Weight Management is built on a different diagnostic premise: that chronic headache is not a single condition but a syndrome with identifiable, treatable structural, neurological, hormonal, and myofascial contributors, and that nerve blocks, image-guided injections, and integrative care coordinated around those contributors can produce durable relief where pharmacological management alone has produced only partial, temporary improvement. Migraine affects approximately 12–15% of Americans, making it one of the most prevalent neurological conditions in the country, yet it remains chronically undertreated, because the standard care pathway stops at medication management long before the structural interventions most likely to help are ever considered.
Close-up of a woman with closed eyes holding her temples, showing signs of a migraine or headacheKey Takeaways
- Migraine affects 12–15% of Americans: with women experiencing it at nearly twice the rate of men (17–19% vs. 6–9%), and more than 75% of all migraine patients report associated neck pain, pointing to the structural and cervicogenic contributors that standard neurological evaluation rarely assesses
- Greater occipital nerve block studies consistently demonstrate efficacy, with over 82% of participants reporting moderate or significant pain relief, and a systematic review finding a 66.6% reduction in pain intensity: outcomes that exceed what most preventive medications achieve in chronic migraine populations
- Sphenopalatine ganglion (SPG) block reaches the parasympathetic relay station that drives the autonomic features of migraine, with one study finding 98.2% headache relief at 15 minutes and 87% of primary care administrations producing meaningful pain reduction with minimal adverse effects
- Hormonal fluctuation: particularly the estrogen withdrawal that precedes menstruation, triggers migraine in up to 70% of female migraineurs, establishing hormonal evaluation as a clinical prerequisite for comprehensive headache treatment, not an optional adjunct
Understanding Migraine: Neurology, Types, and What the Standard Workup Misses
The Neurological Mechanism of Migraine
Migraine is not a headache disorder. It is a neurological disorder in which headache is one phase of a broader episodic event. The underlying mechanism involves cortical spreading depression, a wave of neuronal and glial depolarization that propagates across the cortex and activates the trigeminovascular system, the network of pain-sensitive nerve fibers surrounding the meningeal blood vessels whose activation produces the throbbing, pressure, and photophonic sensitivity that characterize the migraine headache phase. Calcitonin gene-related peptide (CGRP), released by activated trigeminal nerve fibers, is the primary neurochemical driver of migraine pain, which explains both why CGRP-targeting medications are effective and why the nerve blocks that interrupt trigeminal and occipital signaling pathways can abort attacks without any pharmacological mechanism at all.
What most standard headache evaluations do not assess is the structural amplification layer: the cervical facet joints, suboccipital musculature, and posterior cervical ligamentous complex that feed nociceptive input into the trigeminocervical complex, the anatomical convergence zone where upper cervical nerve signals and trigeminal signals merge and where structural pathology in the neck becomes indistinguishable from migraine at the neurological level. For patients whose migraines are amplified or initiated by cervical pathology, treating the headache without treating the neck is treating the symptom without the source.
Migraine Types and the Treatment Implications
Episodic migraine, defined as fewer than 15 headache days per month, and chronic migraine, 15 or more headache days per month for at least three months, with migraine features on at least eight of those days, differ not only in frequency but in their responsiveness to different treatment approaches. Chronic migraine affects an estimated 1–4% of the general population, a subset that has typically exhausted multiple oral preventive medication trials and for whom interventional procedures represent not a last resort but the clinically appropriate next step.
The major migraine subtypes that interventional care most effectively addresses include: chronic migraine with cervicogenic overlay, where structural neck pathology amplifies attack frequency and severity; menstrual migraine, driven by the estrogen withdrawal that precedes menstruation in 18–25% of female migraineurs; vestibular migraine, characterized by vertigo, gait instability, and spatial disorientation alongside or instead of headache; and new daily persistent headache, a pattern that often responds poorly to standard migraine medications but improves with nerve block and trigger point approaches targeting the myofascial and structural contributors that initiated the pattern.
The Anatomy of Chronic Headache: What Standard Imaging Misses
Standard MRI and CT imaging of the brain in migraine evaluation serves an important purpose, ruling out structural intracranial pathology, and a significant limitation: it does not evaluate the cervical structures, myofascial trigger points, hormonal environment, or autonomic nervous system dysregulation that drive the majority of chronic headache presentations. Patients with normal brain imaging who are told that nothing was found are frequently patients whose headache generators are in the cervical spine, posterior cervical musculature, or hormonal system, structures that standard neurological workup is not designed to evaluate and that respond to the targeted interventional and integrative treatment that RegenLife's diagnostic services and interventional procedures are designed to provide.
Why Conventional Migraine Treatment Falls Short for Chronic Sufferers
The Medication Trial Cycle
The standard pharmacological approach to migraine management progresses through a sequence that most chronic sufferers know well: acute abortive medications (triptans, NSAIDs, ergotamines) for individual attacks, escalating to oral preventive medications (beta-blockers, anticonvulsants, tricyclic antidepressants) when attack frequency justifies daily treatment. These medications are appropriate and effective for a substantial proportion of migraine patients, and genuinely insufficient for the chronic migraine population, in whom preventive medication response rates rarely exceed 50% and in whom the cumulative medication burden of years of acute abortive use can itself perpetuate the headache cycle through medication overuse headache.
Medication overuse headache, also called rebound headache, occurs when frequent use of acute migraine medications, typically more than 10–15 days per month, paradoxically increases attack frequency rather than reducing it. The patient who reaches for a triptan or NSAID more than ten days per month to manage an already-frequent migraine pattern is sustaining the neurological sensitization that makes attacks more frequent, more severe, and increasingly medication-refractory, a cycle that interventional procedures can help interrupt precisely because they work through mechanisms other than pharmacological suppression.
The Gap Between Neurology Referral and Interventional Care
For patients who have failed two or three oral preventive medications, the standard referral pathway leads to subspecialty neurology evaluation and, increasingly, to CGRP monoclonal antibody therapy or OnabotulinumtoxinA (Botox) injections, both effective preventive treatments for chronic migraine that have significantly expanded what pharmacological prevention can accomplish. What they do not provide is evaluation and treatment of the structural, cervicogenic, myofascial, and hormonal contributors to chronic headache, contributors that, when present and unaddressed, explain why some patients respond only partially even to CGRP inhibitors and Botox, and why others continue to have frequent breakthrough attacks despite biological prevention.
The pain management and interventional approach at RegenLife fills this gap, not by replacing appropriate pharmacological management but by identifying and treating the structural and physiological contributors that medications cannot address, creating the conditions in which all treatments, pharmacological and interventional, can work more effectively.
Nerve Blocks for Migraine and Headache Treatment in Cincinnati OH
A healthcare worker administering an injection to a patient in a clinical settingThe Greater Occipital Nerve Block: Mechanism and Evidence
The greater occipital nerve (GON) emerges from the C2 nerve root and travels through the suboccipital musculature to supply sensory innervation to the posterior scalp. Its relevance to migraine lies in the trigeminocervical complex, the anatomical convergence zone in the upper cervical spinal cord where C1, C2, and C3 afferents converge with descending trigeminal nucleus fibers, creating a bidirectional pain highway between the neck and the head. By blocking the greater occipital nerve at its emergence point, the GON block interrupts this afferent input, reducing the sensitization signal that drives both attack initiation and central sensitization.
The clinical evidence for greater occipital nerve block in migraine is now substantial. A systematic review and meta-analysis examining GON block for chronic migraine found statistically significant reductions in headache frequency, intensity, and duration compared to placebo across 12 randomized controlled trials, with 11 of the 12 demonstrating efficacy. A large retrospective cohort study documented that over 82% of participants reported moderate or significant pain relief following occipital nerve block treatment, with a mean duration of effect of 55.3 days, a timeframe that, with repeated treatment, translates to sustained reduction in migraine burden. A 2024 systematic review specifically examining GON block for chronic migraine prevention found a 66.6% reduction in pain intensity in the best-performing study arm.
For cervicogenic headache, where the GON block is most precisely mechanism-matched, a study of 47 patients found that 87% required more than one injection to achieve a six-month pain-relief period, establishing the repeated-block protocol as the appropriate standard for structural headache presentations rather than a single diagnostic injection.
The Sphenopalatine Ganglion Block: Reaching the Parasympathetic Relay
The sphenopalatine ganglion (SPG) is a parasympathetic ganglion embedded in the pterygopalatine fossa, just posterior to the nasal turbinates. It serves as a critical relay station for the parasympathetic outflow that drives the autonomic features of migraine, the tearing, nasal congestion, and periorbital fullness that accompany severe attacks, and its connections to both trigeminal and facial nerve pathways make it a particularly comprehensive intervention point for complex headache presentations.
SPG block can be delivered through two routes: transnasal (using a catheter or applicator to deliver local anesthetic through the nasal passage) or image-guided injection to the pterygopalatine fossa. A study of 55 patients receiving SPG block found that 70.9% became headache-free at 15 minutes, with a headache relief rate, defined as 50% or greater reduction in pain intensity, of 98.2% at both 15 minutes and 2 hours. A 2025 review of SPG block implementation in primary care settings found that 87% of administrations resulted in meaningful pain relief with minimal adverse effects, including the transient nasal numbness and throat discomfort that typically resolve within 30–60 minutes of the procedure.
The SPG block's mechanism, interrupting both the trigeminal-parasympathetic reflex arc and the direct parasympathetic input to meningeal vessels, makes it particularly effective for migraine presentations featuring prominent autonomic symptoms, for cluster headache (where parasympathetic overactivation is a defining feature), and for new daily persistent headache presentations where trigeminal sensitization has become self-sustaining. The interventional procedures at RegenLife evaluate SPG block indication within the broader headache diagnostic assessment that identifies each patient's specific pain generators and mechanism profile.
Trigger Point Injections and the Myofascial Layer
The connection between pericranial and cervical myofascial trigger points and headache frequency is one of the most consistently documented and consistently undertreated relationships in headache medicine. Trigger points in the trapezius, sternocleidomastoid, suboccipital, and temporalis muscles generate referred pain patterns that reproduce migraine, and their activation by stress, postural loading, or sleep disruption directly lowers the threshold for migraine attack initiation in sensitized patients. For many patients with frequent episodic or chronic migraine, the myofascial layer is not simply a symptom of their migraines. It is an active precipitating and amplifying contributor to their attack frequency.
Trigger point injections targeting the pericranial and cervical musculature can reduce attack frequency by eliminating the peripheral nociceptive input that lowers the migraine threshold, addressing a contributor that neither oral preventive medications nor CGRP biologics specifically target. Combined with the GON block or SPG block in patients whose presentations involve both neurological and myofascial contributors, trigger point injection completes the interventional picture of comprehensive headache treatment.
Cervicogenic Headache: When the Neck Is Driving the Pain
Distinguishing Cervicogenic from Migraine
Cervicogenic headache is referred pain from an identified structural source in the cervical spine, most commonly the C2–C3 facet joint, whose innervation by the C3 dorsal ramus and third occipital nerve places it in direct anatomical relationship with the greater occipital nerve and the suboccipital musculature. The clinical features that distinguish cervicogenic headache from migraine include unilateral pain that does not switch sides, onset with specific neck movements or sustained neck posture, reproduction of the headache by manual pressure on the cervical spine, and restricted cervical range of motion, features that point toward a structural rather than purely neurological generator.
The diagnostic standard for cervicogenic headache requires abolition of the headache following neural blockade of the suspected cervical pain generator, a diagnostic criterion that simultaneously serves as the initial treatment step. When a GON block or C2–C3 medial branch block eliminates the headache for the expected duration of the anesthetic, the cervical origin is confirmed and treatment is directed at the structural level rather than managed pharmacologically as if the presentation were primary migraine.
Structural Cervical Contributors and Regenerative Options
For patients with confirmed cervicogenic headache whose pain originates from facet joint degeneration or posterior capsular injury, particularly common after motor vehicle accidents, in patients with prior cervical trauma, and in those with established cervical spondylosis, the GON block addresses the nerve rather than the joint. Intra-articular cervical facet PRP injection targets the structural pain generator directly, initiating the repair response in damaged facet capsule tissue that nerve block cannot provide. The approach to cervical facet injury and its relationship to headache is detailed in the whiplash treatment context, where the same facet-mediated cervicogenic mechanism underlies a substantial proportion of post-accident chronic headache.
Prolotherapy targeting the posterior upper cervical ligament insertions addresses the suboccipital traction headache mechanism, restoring the structural integrity that prevents the muscular overload and referred headache pattern that overstretched upper cervical ligaments generate through their suboccipital attachments. For patients whose cervicogenic headaches have a clear ligamentous instability component, worsening with sustained neck posture, improvement with cervical support, associated dizziness or visual disturbance. This structural approach often produces the durable relief that nerve block alone does not sustain.
Hormonal, Autonomic, and Systemic Contributors to Chronic Headache
A doctor attentively listens to a patient during a medical consultation, emphasizing care and understandingEstrogen, Hormonal Fluctuation, and Migraine Susceptibility
The sex distribution of migraine, women experiencing it at 17–19% prevalence versus 6–9% in men, a ratio that emerges at puberty and narrows after menopause, is not incidental. Estrogen directly modulates the excitability of trigeminal neurons and influences CGRP release; the rapid withdrawal of estrogen that precedes menstruation lowers the migraine threshold and triggers attacks in a predictable pattern that affects up to 70% of female migraineurs around the perimenstrual period. Perimenopause, characterized by erratic estrogen fluctuation rather than stable deficiency, is particularly associated with migraine worsening, with new-onset migraine or dramatic increase in attack frequency being among the most common neurological complaints of the menopausal transition.
Hormone therapy evaluation at RegenLife examines the full sex hormone picture, estradiol, progesterone, testosterone, and DHEA-S, alongside thyroid function and fasting metabolic markers, identifying the hormonal contributors that drive headache frequency independently of the structural and neurological generators. Stable estrogen delivery through transdermal rather than oral routes, which avoids the first-pass hepatic effect that reduces estrogen bioavailability and increases clotting risk, is the approach most consistently associated with migraine improvement in hormonally driven presentations.
Autonomic Nervous System Dysregulation and Central Sensitization
Chronic migraine does not exist in neurological isolation. The autonomic nervous system drives the parasympathetic features of severe attacks, the tearing, rhinorrhea, and cutaneous allodynia that indicate advanced trigeminovascular activation, and sustained sympathetic dysregulation from chronic pain, sleep disruption, and psychological stress maintains the state of central sensitization that makes the nervous system increasingly prone to generating migraine from progressively lower-threshold stimuli. Patients with chronic migraine who have not responded adequately to pharmacological prevention often carry a significant autonomic burden, measurable through heart rate variability analysis, that predicts poor treatment response until it is addressed as an independent target.
ANS testing at RegenLife quantifies this autonomic imbalance objectively, guiding the BrainTap neurostimulation and behavioral health interventions that recalibrate the nervous system environment in which all other headache treatments must operate. For patients with comorbid anxiety, post-traumatic stress, or significant sleep disruption, conditions documented in a substantial proportion of chronic migraine patients. This autonomic and psychological layer is not secondary to the neurological treatment: it is a prerequisite for it.
Systemic Inflammation, Metabolic Health, and Headache Frequency
Systemic inflammatory burden, from insulin resistance, visceral adiposity, dysbiotic gut microbiome, and chronic metabolic disease, directly amplifies headache frequency through central sensitizing compounds and prostaglandin-mediated neuroinflammation. Obesity is associated with a two- to fivefold increase in the risk of migraine chronification, the transformation from episodic to chronic migraine, a relationship that runs through both mechanical and inflammatory pathways. Patients with uncontrolled blood glucose, elevated high-sensitivity CRP, and significant visceral adiposity carry a baseline inflammatory state that raises the trigeminovascular sensitivity floor, making attacks more frequent and more severe than the same neurological vulnerability would produce in a metabolically healthier patient.
The lifestyle medicine program at RegenLife addresses this systemic inflammatory burden as part of the comprehensive headache treatment protocol, not as a weight management adjunct but as a direct neurological intervention, because reducing the inflammatory contributors to central sensitization produces measurable reductions in migraine frequency that pharmacological treatment alone cannot replicate.
Physical Rehabilitation, Manual Care, and Comprehensive Headache Management
Professional massage therapist performing therapeutic neck massage on female patient, relieving neck tensionPhysical Therapy for Migraine and Cervicogenic Headache
More than 75% of people with migraine experience associated neck pain, and many report muscle tension, neck stiffness, and jaw dysfunction, a clinical picture that reflects the bidirectional relationship between cervical musculoskeletal pathology and migraine susceptibility. Physical therapy targeting the deep cervical flexors, postural alignment, and cervicocentric gaze stabilization reduces both the cervical input that amplifies trigeminovascular sensitization and the proprioceptive disruption that drives the vestibular symptoms and dizziness that complex migraine presentations often include.
Physical therapy at RegenLife targets the specific neuromuscular findings in each patient's headache presentation, deep cervical flexor weakness that increases mechanical loading on the upper cervical segments, forward head posture that compresses suboccipital structures and elevates posterior cervical muscle tension, and the respiratory and movement pattern dysfunctions that sustain the sympathetic activation state in which migraine attacks occur more readily. A systematic review found that manual therapy and physical therapy may produce comparable preventive effects to conventional medications like propranolol in episodic migraine, establishing these interventions as first-line options for patients seeking non-pharmacological approaches or augmenting pharmacological prevention with structural management.
Chiropractic Care and Cervical Joint Mechanics
Cervical segmental restriction, the hypomobile joint dysfunction that develops as a compensatory response to instability, injury, or chronic poor posture, generates its own afferent input into the trigeminocervical complex and refers pain into the occipital and temporal regions in patterns that either mimic or amplify migraine. Chiropractic care addresses these restricted segments through targeted manipulation and mobilization that restores normal segmental motion, reduces the referred pain that restriction generates, and creates the movement environment in which nerve block treatment and physical therapy rehabilitation produce their full cumulative benefit.
The sequencing matters: for patients with confirmed upper cervical ligamentous instability, manipulation of hypermobile segments without first addressing structural integrity can exacerbate the instability pattern. The appropriate sequence, interventional treatment and prolotherapy to restore structural stability, then chiropractic mobilization to restore normal motion, then neuromuscular rehabilitation to build the dynamic stabilization that protects recovered structures, reflects the same biological logic that applies to every musculoskeletal component of the headache treatment protocol.
Massage Therapy, Myofascial Release, and the Pericranial Burden
The hypertonic, trigger-point-laden state of the pericranial and posterior cervical musculature in chronic migraine patients is not simply a consequence of frequent attacks. It is an active contributing factor that sustains attack frequency by maintaining the peripheral nociceptive input that drives central sensitization. Massage therapy targeting the posterior cervical, suboccipital, trapezius, and temporalis musculature reduces this myofascial burden, not as the primary treatment for the neurological disorder but as an essential component of the whole-person recovery program that creates the conditions in which interventional and rehabilitative treatment produces its maximum effect.
The Integrated Evaluation at RegenLife: Migraine and Headache Treatment Cincinnati OH
Effective migraine and headache treatment in Cincinnati, OH begins with an evaluation designed to identify all contributing factors, not the most obvious one alone. At RegenLife, the assessment process examines the structural contributors (cervical facet integrity, myofascial trigger points, ligamentous instability), the neurological pathway (trigeminal sensitization pattern, attack frequency and morphology), the hormonal environment (full sex hormone panel, thyroid function, metabolic markers), and the autonomic state (ANS testing for sympathovagal balance and central sensitization load) simultaneously. This diagnostic breadth reflects the clinical reality that chronic migraine is almost never generated by a single factor, the patient with frequent migraine also commonly carries cervicogenic amplification from unaddressed neck pathology, hormonal fluctuation from perimenopausal estrogen instability, and metabolic inflammation that sustains neurological sensitization around the clock.
The interventional procedures, GON block, SPG block, trigger point injection, and where indicated, cervical facet PRP or prolotherapy, are selected and sequenced based on the diagnostic findings rather than applied uniformly to all headache presentations. The diagnostic services that guide treatment selection, the interventional procedures that address the identified neurological and structural generators, the physical therapy and chiropractic care that restore neuromuscular function, and the hormone therapy and lifestyle medicine that address the systemic environment, coordinated under one practice rather than distributed across disconnected specialty referrals, represent the clinical structure that the complexity of chronic migraine actually requires.
Contact RegenLife Centers to schedule an evaluation or ask which service fits your needs.
Frequently Asked Questions
Find answers to common questions
Ready to Learn More?
To learn more and to find out if you might be a good candidate at RegenLife, schedule a consultation with our team today.
About the Author

Caitlyn Benton, Research Manager at RegenLife
As Research Manager, Caitlyn Benton oversees the strategic planning and execution of clinical research projects, ensuring all studies adhere to the highest regulatory and ethical standards. With expertise in protocol development and data monitoring, she coordinates multidisciplinary teams to ensure the integrity of our clinical research programs and the accuracy of the insights shared with our patients.
Reviewed and Approved by

Dr. Zeeshan Tayeb, Medical Director at RegenLife
Interventional Spine, Pain, and Sports Medicine Dr. Zeeshan Tayeb, MD is board-certified in Pain Medicine and Physical Medicine & Rehabilitation, with specialized fellowship training in interventional spine, pain, and sports medicine. He sees patients at Pain Specialists of Cincinnati/RegenLife in Cincinnati, Ohio. Dr. Tayeb's background in physical medicine and rehabilitation has provided the foundation for his comprehensive approach to treating the whole person. Dr. Tayeb has done extensive training and education in both functional and regenerative medicine and specializes in state-of-the-art treatments, including laser therapies, PRP and stem-cell injections, and nutritional and hormonal optimization.
Disclaimer:
As a service to our readers, RegenLife provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
Stay Updated With Our Latest News
Check back regularly for new articles and updates about pain management treatments, practice news, and health tips from our team of specialists.
Get In Touch
Same-week consults. Real follow-through.
Tell us what's going on. A coordinator will follow up during office hours to help book your visit.
Choose the clinic that works for you.
Most new patients can be seen within the same week.
We accept most major insurance plans